Spinal Cord Stimulators (SCS) represent the largest segment of the industry. Their dominance is driven by their high effectiveness in managing chronic pain and post-surgical neuropathies, as well as their increasing role as a non-opioid alternative for long-term pain management.
Growth is primarily fueled by the rising prevalence of chronic neurological disorders (such as Parkinson’s and epilepsy), an aging global population, the demand for alternatives to pharmacological treatments, and technological advancements in device miniaturization and battery life.
AI is being integrated to create "smart" solutions, including adaptive algorithms and real-time interpreters of neural feedback. These technologies allow for personalized, therapist-independent therapeutic delivery and closed-loop stimulation, which optimizes treatment based on physiological input.
North America remains the dominant market due to its advanced clinical infrastructure, high patient awareness, favorable reimbursement frameworks (such as FDA breakthrough device designations), and the presence of major industry players like Medtronic, Abbott, and Boston Scientific.
The Asia-Pacific (APAC) region is the fastest-growing market. This growth is attributed to rapid urbanization, increasing healthcare expenditure, government incentives for neurotech startups, and expanding infrastructure for advanced neurotherapeutics in countries like China, India, and Japan.
The market faces challenges such as the high cost of implantable devices and surgical procedures, complex regulatory pathways, and a lack of skilled neurosurgeons and specialized infrastructure, particularly in developing or rural regions.
In 2024, Medtronic unveiled the Percept-PC system with BrainSense technology for movement disorders; Boston Scientific received CE Mark for its WaveWriter Alpha spinal cord stimulation platform; and Abbott received FDA approval for its NeuroSphere Virtual Clinic, which enables remote device programming.
While traditionally used for Parkinson’s disease, DBS is increasingly being adopted for neuropsychiatric conditions, including treatment-resistant depression, obsessive-compulsive disorder (OCD), dystonia, and epilepsy, supported by upgrades in sensing-enabled electrodes.
Hospitals and ASCs are the leading end-use segments because they possess the advanced surgical infrastructure and multidisciplinary teams required for complex implantation. ASCs, in particular, are gaining traction as a cost-effective outpatient alternative for neuromodulation procedures in developed economies.
